@NTA_Exams Forcing #NEETstudent to again Update Refund #BankDetails to download AdmitCard, even if already updated #WHY??? It also has #NEWLink to #OptOut of Refund #WHY??? Form shared by a student showing 3 Red Circled Links Doing same thing #OptOut of #Refund #NTASCAM ??

28/ „At the center of the controversy is NewLink Genetics, a small company in Ames, Iowa, that bought a license to the vaccine's commercialization from the Canadian government in 2010, and is now suddenly caught up in what WHO calls ‚the most severe acute public health emergency seen in modern times.‘ Becker and others say the company has been dragging its feet the past 2 months because it is worried about losing control over the development of the vaccine. But Brian Wiley, vice president of business development at NewLink Genetics, says the company is doing all it can. ‚Our program has moved forward at an unprecedented pace,‘ he says. Even if it took another few months, ‚we would still be breaking a record in terms of getting this into patients.‘“ …

Civic forums need to conduct Meets every month in PressClub about need of Efficient integrated #PublicTransit systems till Last mile connectivity, Efficient MMTS services, NewLink rds & , ServiceRoads around busy junctions etc @JP_LOKSATTA @KVishReddy @kishanreddybjp @hmtvnews

x.com/ross64x/status/2059187… Resulta que Plus Ultra, esa aerolínea de 650 empleados que milagrosamente ha renovado su flota con siete flamantes Airbus A330. Tras ser bendecida con el rescate público de la SEPI en marzo de 2021, la compañía sintió el irrefrenable impulso de comprar, de forma sostenida y generosa, espacios publicitarios en la prensa escrita (ABC, El Mundo), ondas radiofónicas (COPE, Onda Cero) y hasta en los platós de televisión (con especial cariño por El Toro TV y el chiringuito de jugones de Julio Ariza). El clímax de esa apariencia de simular una línea aérea llegó el 14 de mayo de 2024, fecha en la que presentaron en sociedad su campaña internacional más ambiciosa e institucional, minuciosamente diseñada por la multinacional Newlink Spain. Con los descomunales carteles de exteriores inundaron marquesinas, pantallas televisivas y plataformas digitales en España, todo en un titánico esfuerzo por consolidar la marca ante el codiciado público hispanoamericano, coincidiendo con el estreno de su ruta entre Madrid y Buenos Aires. Y es que, claro, de alguna manera tenían que desmentir el perverso mito popular de que el dinero del rescate se había esfumado entre ostras y señoritas de compañía.

雪泉和風バニーのtkbですが、温めても捲れるのはフリルで、肝心の着物が接着されているのか捲れません。つまりNewLinkやNewTouの確認が出来ず、飛鳥の様に着物を温めて８１丸出しは出来ないです。orz 着物まで捲れた方いますか？ 自分が確認出来るのはこの写真までです。 #シノマス #閃乱カグラ

Robert Malone’s role during the Ebola vaccine push Robert W. Malone appears in the rVSV-ZEBOV story as an accelerator, project-management and deal-structuring figure during the emergency phase of the West African Ebola outbreak. According to his own resume, he worked on the Ebola vaccine project for NewLink/BioProtection Systems, specifically the rVSVdG-ZEBOV Ebola vaccine project, which he says resulted in well over $100 million in non-dilutive capital for NewLink/BioProtection Systems. His stated role also included working with the World Health Organization (WHO) and helping with the initial setup of the licensing deal to Merck Vaccines. This aligns with a 2015 LinkedIn post praising Malone’s role, which credits him with helping move the “orphan” PHAC/rVSV-ZEBOV vaccine project forward after August 2014, when DTRA, USAMRIID and other actors sought to rapidly advance an Ebola vaccine candidate. - James M. Wilson The post further credits Malone with helping develop contracts, bringing in Focus Diagnostic Clinical Trials, connecting USAMRIID/WRAIR immunoassay and clinical-trial work, putting WHO leadership in contact with Pentagon leadership, involving Norway in clinical-research funding, recruiting Merck Vaccines into the project, assembling a management team, and helping develop BARDA and DTRA contracts reportedly worth more than $200 million. This places Malone not at the center of the later African efficacy trials as a visible principal investigator, but in the earlier crisis-response machinery: contracting, coordination, funding acquisition, trial-enabling infrastructure, WHO liaison work, and the transition of the Canadian PHAC/NewLink rVSV-ZEBOV vaccine candidate into a Merck-led global development programme. His role therefore belongs in the operational-financial layer of the Ebola vaccine story, alongside DTRA, USAMRIID, WRAIR, PHAC, WHO, Norway, BARDA, NewLink/BioProtection Systems and Merck.

#好きなゲーム5個載せて1つでも知ってるのあったらRT ブルーアーカイブ シノビマスター閃乱カグラNewLink ドルフィンウェーブ 東方ロストワード ららマジ

Sergio Roitberg, presidente de Newlink Group, nos acompañará este sábado en #AbanicoSocial para hablarnos sobre el #PensamientoOrbital, aquello que cada día nos mueve en un mundo híper conectado y de constante cambio.

When they get a plushie..... "When an Ebola outbreak emerged in Western Africa in early 2014, Canada offered its experimental vaccine to the World Health Organization (WHO). The organization, however, declined this vaccine, as well as one that was under development by GlaxoSmithKline (GSK). A few days after the WHO declared the Ebola outbreak a global health emergency, the Canadian government announced that it would be donating the experimental vaccine to the agency.4 The vaccine, however, had never been tested in clinical trials, and while drug companies have an extensive history of using experimental products on persons living in developing countries, WHO decided that clinical trials would be necessary. NewLink Genetics had never conducted large-scale clinical trials and as a result, WHO and other world leaders pushed for the company to partner with or sell the vaccine rights to a larger pharmaceutical company. In late 2014, Merck pharmaceuticals bought the Ebola vaccine rights for $50 million."

飛鳥和風バニーの81出しについて。 １枚目　昨日夕方に詰め物入れて形状を慣らすために半日放置して朝５時前に詰め物外す。 ２枚目　二度寝して２時間後の状態。 完全に81出して飾るのは不可で、NewLinkチラ見せで飾る形になります。ただ、衣装と本体を離せたので経年の色移り防止になります。

飛鳥和風バニーのtkbはエロいです。 NewLinkがエロい。 ８１出して飾るためにテスト中。 温めて柔らかくして、間に詰め物入れて癖を付ければ８１出して飾れそう。

一騎當千我在看閃亂神樂newlink立繪時這遊戲有跟她們合作

Talking about U.S.-DTRA: Have you seen this from August 6, 2015? Robert "Bob" Malone, Ebola and PHAC/rVSV-ZEBOV from Merck? - NewLink Genetics

Hiring agent sa newlink 20% reduction pm now💸

両姫のNEWLINKメニュー台詞一覧 >夜の時報ボイス 「こんばんは、先生」 「今日は月が綺麗ですね」 ^告白？ >季節限定ボイス(冬) 「今日も冷え込みますね、先生」 「こんな時は体を寄せ合いたくなっちゃいませんか？」 ^しれっとスキンシップねだり 雪不帰が勝てるわけないやんこんなん

Robert "Bob" Malone November 24, 2014: Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine Merck, known as MSD outside the United States and Canada, and NewLink Genetics Corporation, announced today that they have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink’s investigational rVSV-EBOV (Ebola) vaccine candidate. The vaccine candidate, originally developed by the Public Health Agency of Canada (PHAC), is currently being evaluated in Phase I clinical trials. Pending the results of ongoing Phase I trials the U.S. National Institutes of Health (NIH) has announced plans to initiate, in early 2015, a large randomized, controlled Phase III study to evaluate the safety and efficacy of the rVSVEBOV vaccine and another investigational Ebola vaccine co-developed by the National Institute of Allergy and Infectious Diseases (NIAID) and GlaxoSmithKline (GSK). “Effective Ebola vaccines will be a critical component of comprehensive prevention and control measures for people at risk of Ebola virus infection and to stem future outbreaks globally,” said Dr. Julie Gerberding, president of Merck Vaccines. “Merck is committed to applying our vaccine expertise to address important global health needs and, through our collaboration with NewLink, we hope to advance the public health response to this urgent international health priority.” According to Dr. Charles Link, chairman and chief executive officer of NewLink Genetics, “Merck’s vaccine developmentexpertise, commercial leadership and history of successful strategic alliances make it an ideal partner to expedite thedevelopment of rVSV-EBOV and, if demonstrated to be efficacious and well-tolerated, to make it available to individuals and communities at risk of Ebola virus infection around the world.” Under the terms of the agreement, Merck will be granted the exclusive rights to the rVSV-EBOV vaccine candidate as well as any follow-on products. The vaccine candidate is under an exclusive licensing arrangement with a wholly-owned subsidiary of NewLink Genetics. Under these license arrangements, the PHAC retains non-commercial rights pertaining to the vaccine candidate. Phase I clinical trials of the rVSV-EBOV vaccine are now underway at the Walter Reed Army Institute of Research (WRAIR) and the NIAID at the NIH. Additional Phase I studies are underway or planned to begin in the near future at clinical research centers in Switzerland, Germany, Kenya, and Gabon in a World Health Organization-coordinated effort, and in Canada by the Canadian Immunization Research Network. “This vaccine is the result of years of hard work and innovation by Canadian scientists. We are pleased that this new alliance coupled with the clinical trials currently underway will further strengthen the possibility that the vaccine will make a difference in the global response to the Ebola outbreak,” said Canada’s Minister of Health, Rona Ambrose. About rVSV Vaccine Platform This vaccine platform is based on an attenuated strain of vesicular stomatitis virus that has been modified to express an Ebola virus protein that plays an essential role in establishing virus infection. The rVSV-EBOV vaccine was created by scientists at the Public Health Agency of Canada’s National Microbiology Laboratory. A significant portion of the funding for the further development of the vaccine came from the CBRN Research and Technology Initiative, a federal program led by Defence Research and Development Canada. In 2010, the PHAC signed a licensing arrangement with BioProtection Systems (BPS), a wholly-owned subsidiary of NewLink Genetics, as the sole licensee for these vaccines and the underlying technology. BPS has worked with the PHAC to produce clinical trial materials and to move this vaccine candidate into Phase I studies. –––––––––– October 10, 2016 Merck partner NewLink grabs up to $76 million in Ebola vax funding from feds The rVSV-ZEBOV vaccine, which Merck & Co. licensed from NewLink in late 2014, won FDA and EMA milestones this summer in a push toward licensure. Merck plans to submit the vaccine for approval by the end of 2017 as part of a partnership with Gavi; through that deal, the Vaccine Alliance will pay $5 million to build a stockpile.

I fully agree, Mark! Have you seen the my findings about the Dutch woman Elizabeth Cathérine Hondius at Merck Sharp & Dome (MSD)? Remember Robert "Bob" Malone and the Ebola-Vaccine? From his résumé: Ebola vaccine project for NewLink & Bioprotection Systems (rVSVdG ZEBOV Ebola vaccine project), resulting in well over 100M USD non-dilutive capital to L/BPS. - rVSV-ZEBOV This also included working with the World Health Organization (WHO) as well as initial set up of the licensing deal to Merck Vaccines of the Ebola vaccine. Did Malone cooperate with the BNITM Hamburg and Marylyn Addo? The Clinical Trial was done there. Philippa Sigl-Glöckner from Munich appears in the EpsteinFiles and worked with Melanie Walker at the World Bank in New York. Just in time for the 2013 / 2014 Ebola outbreak.

【ブラウンダスト2】 トータル2天で 夜桜＋5になりました！ シノマスキャラ全て＋5（完凸）に なりました😆 ちなみに無課金です😍 #ブラウンダスト2 #ブラダス2 #シノマス #閃乱カグラ #NEWLINK #コラボ #イベント

【ブラウンダスト2】 無料ガチャが仕事して 夜桜＋2になりました！ 後は期間中に完凸にします🔥 #ブラウンダスト2 #ブラダス2 #シノマス #閃乱カグラ #NEWLINK #コラボ #イベント